Cabaletta Bio Inc Stock

$1.87

2.09% day before yesterday

Nasdaq, May 30, 10:00 pm CET

ISIN

US12674W1099

Symbol

CABA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Cabaletta Bio Inc Stock price

$1.87

-6.74 78.28% 5Y

Nasdaq, Closing price Fri, May 30 2025

-0.04 2.09%

ISIN

US12674W1099

Symbol

CABA

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$94.89m
Enterprise Value	$-13.63m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.14
P/B ratio (TTM) P/B ratio	0.78
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-134.25m
Free Cash Flow (TTM) Free Cash Flow	$-97.22m
Cash position	$131.83m
EPS (TTM) EPS	$-2.49
P/E forward	negative
P/S forward	21.69
EV/Sales forward	negative
Short interest	11.24%

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Get Started for Free Today

Cabaletta Bio Inc Stock Analysis

Unlock Scores for Free

??

11 Analysts have issued a Cabaletta Bio Inc forecast:

9x Buy

82%

2x Hold

18%

More details on Analyst Estimates Including Price Targets

11 Analysts have issued a Cabaletta Bio Inc forecast:

Buy

82%

Hold

18%

Analyst Estimates with Stock Price Targets

Financial data from Cabaletta Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	30 30	44% 44% -
- Research and Development Expense	104 104	61% 61% -
EBITDA	-129 -129	53% 53% -
- Depreciation and Amortization	4.91 4.91	239% 239% -
EBIT (Operating Income) EBIT	-134 -134	57% 57% -
Net Profit	-127 -127	65% 65% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cabaletta Bio Inc Stock News

Neutral

GlobeNewsWire

●

3 days ago

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4...

Neutral

GlobeNewsWire

●

17 days ago

Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg – – Multiple Phase 1/2 disease cohorts fully enrolled across the RESET™ clinical development p...

Neutral

GlobeNewsWire

●

2 months ago

Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel t...

More Cabaletta Bio Inc News

Company Profile

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

Head office	United States
CEO	Steven Nichtberger
Employees	163
Founded	2017
Website	www.cabalettabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now